

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on Apr 8, 2025

Phospho-GSK3 beta (Ser9) Antibody

RRID:AB_2834439

Type: Antibody

Proper Citation

(Affinity Biosciences Cat# AF2016, RRID:AB_2834439)

Antibody Information

URL: http://antibodyregistry.org/AB_2834439

Proper Citation: (Affinity Biosciences Cat# AF2016, RRID:AB_2834439)

Target Antigen: Phospho-GSK3 beta (Ser9)

Host Organism: rabbit

Clonality: unknown

Comments: Applications: WB, IHC, IF/ICC, IP, ELISA

Antibody Name: Phospho-GSK3 beta (Ser9) Antibody

Description: This unknown targets Phospho-GSK3 beta (Ser9)

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_2834439

Vendor: Affinity Biosciences

Catalog Number: AF2016

Record Creation Time: 20241016T231332+0000

Record Last Update: 20241017T001641+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-GSK3 beta (Ser9) Antibody.

No alerts have been found for Phospho-GSK3 beta (Ser9) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Xu Z, et al. (2024) HECW1 restrains cervical cancer cell growth by promoting DVL1 ubiquitination and downregulating the activation of Wnt/ β -catenin signaling. *Experimental cell research*, 435(2), 113949.

Li R, et al. (2024) Recombinant fibroblast growth factor 4 ameliorates axonal regeneration and functional recovery in acute spinal cord injury through altering microglia/macrophage phenotype. *International immunopharmacology*, 134, 112188.

Xiong YJ, et al. (2023) Poly-L-ornithine blocks the inhibitory effects of fibronectin on oligodendrocyte differentiation and promotes myelin repair. *Neural regeneration research*, 18(4), 832.

Yang B, et al. (2021) The miR-136-5p/ROCK1 axis suppresses invasion and migration, and enhances cisplatin sensitivity in head and neck cancer cells. *Experimental and therapeutic medicine*, 21(4), 317.